News Center

Discover all of the trending news of the Ipsen Group


128 results

Oncology

Latest news on the cabozantinib program

During this conference, Exelixis and Ipsen management and invited guest speakers have reviewed…

Neuroscience

FDA Approval of Dysport® for injection for the tr...

A condition in which there is an abnormal increase in muscle tone or stiffness Spasticity…

Oncology

Positive CHMP opinion for CabometyxTM (cabozantin...

Accelerated review procedure The positive CHMP opinion was adopted following an accelerated review procedure reserved…

Group

Aepodia integrates Ipsen’s R&D Campus in Paris-Sa...

[caption id="attachment_2410" align="alignleft" width="300"] R&D center in Les Ulis[/caption] Aepodia is a solution provider…

Group

Celebration of Ipsen Canadian Headquarters Grand Opening in ...

From left to right: Lyndal Walker, Marc de Garidel, Hon. Dipika Damerla, Cynthia Schwalm, Marc Trouyet. Ipsen will…

Group

Opening of a new manufacturing facility in Russia

The opening ceremony was held with participation of Olga Kazanskaya, Vice-Governor of Saint Petersburg,…

Group

A new R&D center in Cambridge (USA)

Ipsen’s state-of-the-art R&D center is located in Cambridge, one of the world’s most vibrant biomedical…

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021